Abstract
Bisphosphonates have been widely used over the past decade to prevent skeletal complications in breast cancer patients with bone metastases. The skeletal complications associated with bone metastases include severe bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. A number of bisphosphonates, including oral clodronate, intravenous (IV) pamidronate, IV zoledronic acid, and ibandronate have been shown to significantly reduce skeletal complications and palliate bone pain in patients with breast cancer based on placebo-controlled trials. However, only zoledronic acid and pamidronate have been directly compared within a single trial, and zoledronic acid (4 mg via 15- minute infusion) was shown to be significantly more effective than 90 mg pamidronate at reducing the overall risk of skeletal complications in patients with breast cancer. Both IV pamidronate and zoledronic acid are recommended by the American Society of Clinical Oncology for the treatment of malignant bone disease. As we look to the future, the role of bisphosphonates will continue to evolve beyond the prevention of skeletal complications. Encouraging results have recently been reported from studies assessing the effects of bisphosphonates on tumor progression in bone and for the prevention of cancer treatment-induced bone loss.
Keywords: breast cancer, skeletal complications, zoledronic acid, ibandronate, pamidronate, clodronate
Current Cancer Therapy Reviews
Title: Bisphosphonate Therapy for Patients with Breast Cancer
Volume: 1 Issue: 3
Author(s): Allan Lipton
Affiliation:
Keywords: breast cancer, skeletal complications, zoledronic acid, ibandronate, pamidronate, clodronate
Abstract: Bisphosphonates have been widely used over the past decade to prevent skeletal complications in breast cancer patients with bone metastases. The skeletal complications associated with bone metastases include severe bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. A number of bisphosphonates, including oral clodronate, intravenous (IV) pamidronate, IV zoledronic acid, and ibandronate have been shown to significantly reduce skeletal complications and palliate bone pain in patients with breast cancer based on placebo-controlled trials. However, only zoledronic acid and pamidronate have been directly compared within a single trial, and zoledronic acid (4 mg via 15- minute infusion) was shown to be significantly more effective than 90 mg pamidronate at reducing the overall risk of skeletal complications in patients with breast cancer. Both IV pamidronate and zoledronic acid are recommended by the American Society of Clinical Oncology for the treatment of malignant bone disease. As we look to the future, the role of bisphosphonates will continue to evolve beyond the prevention of skeletal complications. Encouraging results have recently been reported from studies assessing the effects of bisphosphonates on tumor progression in bone and for the prevention of cancer treatment-induced bone loss.
Export Options
About this article
Cite this article as:
Lipton Allan, Bisphosphonate Therapy for Patients with Breast Cancer, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574261
DOI https://dx.doi.org/10.2174/157339405774574261 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents From Discovery to Clinical Trials: Treatment Strategies for Central Neuropathic Pain after Spinal Cord Injury
Current Pharmaceutical Design Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Overview of Current Trends and the Future of Thromboprophylaxis in Orthopaedic Surgery
Vascular Disease Prevention (Discontinued) Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Application of Stem Cell Therapy During the Treatment of HIV/AIDS and Duchenne Muscular Dystrophy
Current Stem Cell Research & Therapy Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Doppler Haemodynamics of Cerebral Venous Return
Current Neurovascular Research Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Necessity for Re-Vascularization after Spinal Cord Injury and the Search for Potential Therapeutic Options
Current Neurovascular Research The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Progress on the Biological Activities of Helicid and its Derivatives
Current Organic Chemistry Inhalation Cough Challenge
Current Respiratory Medicine Reviews Regenerative Treatment in Spinal Cord Injury
Current Stem Cell Research & Therapy Magnetic Resonance Elastography
Current Medical Imaging